Differences

This shows you the differences between two versions of the page.

--- home:food:aim_health:aging [04.10.2020] – [Dosage] sallieq
+++ home:food:aim_health:aging [09.14.2022] (current) – external edit 127.0.0.1
@@ Line 10: / Line 10: @@
 ===== with additional studies =====
-Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent of BP lowering.  (({{pubmed>long:16236804}}))
+Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent of BP lowering.  (({{pmid>long:16236804}}))
- Although uncontrolled confounding might still exist, (//this was a short term study//) olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed>long:24516110}}))
+ Although uncontrolled confounding might still exist, (//this was a short term study//) olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pmid>long:24516110}}))
- The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>long:16508590}}))
+ The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pmid>long:16508590}}))
- Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued.  (({{pubmed>long:24772521}}))
+ Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued.  (({{pmid>long:24772521}}))
-Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells.   (in breast cancer)(({{pubmed>long:    26138656}}))
+Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells.   (in breast cancer)(({{pmid>long:    26138656}}))
-Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>long:27082551}}))
+Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pmid>long:27082551}}))
-Administration of olmesartan suppressed the accumulation of macrophages in  brachiocephalic atherosclerotic plaque. (in mice) (({{pubmed>long:    20079903}}))
+Administration of olmesartan suppressed the accumulation of macrophages in  brachiocephalic atherosclerotic plaque. (in mice) (({{pmid>long:    20079903}}))
-Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) (({{pubmed>long:    20074257}}))
+Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) (({{pmid>long:    20074257}}))
-Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.  (({{pubmed>long:24379062}}))
+Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.  (({{pmid>long:24379062}}))
-Replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension. (({{pubmed>long:    19927151}}))
+Replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension. (({{pmid>long:    19927151}}))
-Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}}))
+Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pmid>long:19304450}}))
-Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed>long:26239632}}))
+Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pmid>long:26239632}}))
- In conclusion, there is no robust signal for harm with olmesartan use.  (({{pubmed>long:24535009}}))
+ In conclusion, there is no robust signal for harm with olmesartan use.  (({{pmid>long:24535009}}))
 ==== General research on aging ====
-Holistic vitamin D supplementation with or without calcium is unlikely to be an effective primary prevention strategy for falls or fracture. There has also been high-quality evidence that vitamin D, daily or as a bolus, does not reduce the risk of cardiovascular events. (({{pubmed>long:30601231}}))
+Holistic vitamin D supplementation with or without calcium is unlikely to be an effective primary prevention strategy for falls or fracture. There has also been high-quality evidence that vitamin D, daily or as a bolus, does not reduce the risk of cardiovascular events. (({{pmid>long:30601231}}))
-When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status.  Falls studies have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, recurrent falls, and injurious falls. (({{pubmed>long:25539567}}))
+When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status.  Falls studies have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, recurrent falls, and injurious falls. (({{pmid>long:25539567}}))
 ==== Some of the documented protective effects of ARBs ====
  include the ability to:
-  * decrease the incidence and progression of Alzheimer's disease and dementia(({{pubmed>long:20068258}}))
+  * decrease the incidence and progression of Alzheimer's disease and dementia(({{pmid>long:20068258}}))
-  * prevent migraines(({{pubmed>long:12503978}}))
+  * prevent migraines(({{pmid>long:12503978}}))
-  * inhibit liver fibrosis and aid liver healing(({{pubmed>long:12871826}}))
+  * inhibit liver fibrosis and aid liver healing(({{pmid>long:12871826}}))
-  * reduce insulin resistance in rats(({{pubmed>long:15127887}}))
+  * reduce insulin resistance in rats(({{pmid>long:15127887}}))
-  * **6 mg/kg** olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed>long:23775504}}))
+  * **6 mg/kg** olmesartan reduces the inflammatory process and bone loss in rats(({{pmid>long:23775504}}))
-  * protect the mitochondria from age-associated damage from oxidation(({{pubmed>long:12709417}}))
+  * protect mitochondria from age-associated damage from oxidation(({{pmid>long:12709417}}))
-  * play a protective role against proliferative diabetic retinopathy (({{pubmed>long:17560613}}))
+  * play a protective role against proliferative diabetic retinopathy (({{pmid>long:17560613}}))
-  * reduce liver fibrosis(({{pubmed>long:19303015}}))
+  * reduce liver fibrosis(({{pmid>long:19303015}}))
-  * treatment of anxiety and stress-related disorders(({{pubmed>long:15837532}}))
+  * treatment of anxiety and stress-related disorders(({{pmid>long:15837532}}))
-  * reduce oxidative damage(({{pubmed>long:21504378}})) and limit aging (({{pubmed>long:19763608}})) (({{pubmed>long:22283774}}))
+  * reduce oxidative damage(({{pmid>long:21504378}})) and limit aging (({{pmid>long:19763608}})) (({{pmid>long:22283774}}))
@@ Line 63: / Line 63: @@
 to block various bad effects of Angiotensin II, including heart failure. In this regard, olmesartan has been shown to:
-  * protect the heart from damage from inflammation in myocarditis(({{pubmed>long:16336207}}))
+  * protect the heart from damage from inflammation in myocarditis(({{pmid>long:16336207}}))
-  * ameliorate acute experimental autoimmune myocarditis, in rats, suppressing cytotoxic myocardial injury (({{pubmed>long:15879491}}))
+  * ameliorate acute experimental autoimmune myocarditis, in rats, suppressing cytotoxic myocardial injury (({{pmid>long:15879491}}))
-  * prevent acute left ventricular dysfunction(({{pubmed>long:15297251}}))
+  * prevent acute left ventricular dysfunction(({{pmid>long:15297251}}))
-  * lower C-reactive protein, one of the acute phase proteins that increase during systemic inflammation(({{pubmed>long:16939632}}))
+  * lower C-reactive protein, one of the acute phase proteins that increase during systemic inflammation(({{pmid>long:16939632}}))
-  * act as an antiarrhythmic(({{pubmed>long:16094406}}))
+  * act as an antiarrhythmic(({{pmid>long:16094406}}))
-  * block the production of Angiotensin II, thus improving mortality rates in heart failure patients(({{pubmed>long:16534230}}))
+  * block the production of Angiotensin II, thus improving mortality rates in heart failure patients(({{pmid>long:16534230}}))
-  * This study demonstrated that olmesartan reduced angiotensin II and aldosterone levels more effectively than azilsartan, resulting in a stable antihypertensive effect. Olmesartan also had an inhibitory effect on cardiac hypertrophy. Accordingly, it may be effective for patients with increased RAAS activity after cardiac surgery or patients with severe cardiac hypertrophy.  (({{pubmed>long:27086671}}))
+  * This study demonstrated that olmesartan reduced angiotensin II and aldosterone levels more effectively than azilsartan, resulting in a stable antihypertensive effect. Olmesartan also had an inhibitory effect on cardiac hypertrophy. Accordingly, it may be effective for patients with increased RAAS activity after cardiac surgery or patients with severe cardiac hypertrophy.  (({{pmid>long:27086671}}))
-  * Conclusion: In the present study, left ventricular hypertrophy and on arterial compliance were inhibited by a decrease in angiotensin II and aldosterone due to the change-over to olmesartan. In the future, protective effects on organs will be clarified by long-term observations.  (({{pubmed>long:21881353}}))   (({{pubmed>long:24600204}}))
+  * Conclusion: In the present study, left ventricular hypertrophy and on arterial compliance were inhibited by a decrease in angiotensin II and aldosterone due to the change-over to olmesartan. In the future, protective effects on organs will be clarified by long-term observations.  (({{pmid>long:21881353}}))   (({{pmid>long:24600204}}))
@@ Line 81: / Line 81: @@
 In August 2002, Trevor Marshall and Frances  Marshall published a NetPrint about valsartan (Diovan), in which they reported that the once daily dosing of the ARB caused psychedelic dreams and psychotic events in two sarcoidosis patients. On the theory that these symptoms were caused by changes in plasma concentration, the frequency of the dosing of ARB was increased, which ended up reducing symptoms of disease including psychedelic dreams. This early insight into ARBs anti-inflammatory effects led Marshall to conclude that for an ARB to provide symptomatic relief, it was necessary to use more frequent dosing than typical. Professor Marshall would later go on to recommend frequent dosing of another ARB, olmesartan.
-In rats, Olmesartan at 6 mg/kg optimally reduced the inflammatory process and bone loss(({{pubmed>long:23775504}})).  That would be 9-10 tablets of Olmetec daily for a 64 Kg human !
+In rats, Olmesartan at 6 mg/kg optimally reduced the inflammatory process and bone loss(({{pmid>long:23775504}})).  That would be 9-10 tablets of Olmetec daily for a 64 Kg human **!**
 For those with gastric issues, it is recommended that the pill be crushed and mixed with applesauce or similar to reduce impact on gastric lining.
@@ Line 96: / Line 95: @@
 === Olmesartan has also been shown to ===
-  * prevent or delay left ventricular remodeling and hypertrophy in patients with type 2 diabetes  (({{pubmed>long:25275251}}))
+  * prevent or delay left ventricular remodeling and hypertrophy in patients with type 2 diabetes  (({{pmid>long:25275251}}))
-  * reduce the volume of atherosclerotic plaques(({{pubmed>long:19124398}})) (({{pubmed>long:20202514}}))
+  * reduce the volume of atherosclerotic plaques(({{pmid>long:19124398}})) (({{pmid>long:20202514}}))
-  * mildly reduce the risk of stroke in people at high risk for strokes (cerebrovascular events).(({{pubmed>long:19892999}}))
+  * mildly reduce the risk of stroke in people at high risk for strokes (cerebrovascular events).(({{pmid>long:19892999}}))
-  * significantly remodel and destiffen the arterial wall material during long-term treatment (({{pubmed>long:25001274}}))
+  * significantly remodel and destiffen the arterial wall material during long-term treatment (({{pmid>long:25001274}}))
@@ Line 106: / Line 105: @@
 that olmesartan possesses various ways of protecting the kidneys from the effects of inflammation and cytokine damage:
-  * in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{pubmed>long:23511341}}))
+  * in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{pmid>long:23511341}}))
-  * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed>long:23154587}}))
+  * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pmid>long:23154587}}))
-  * results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis (({{pubmed>long:22149003}}))
+  * results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis (({{pmid>long:22149003}}))
-  * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}}))
+  * renal protective effects of olmesartan may be better than those of other ARBs (({{pmid>long:24384547}}))
-  * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects  (({{pubmed>long:24842388}}))
+  * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects  (({{pmid>long:24842388}}))
@@ Line 117: / Line 116: @@
-  * treatment with olmesartan inhibited bone loss  (({{pubmed>long:25363367}}))
+  * treatment with olmesartan inhibited bone loss  (({{pmid>long:25363367}}))
-  * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}}))
+  * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pmid>long:25904217}}))
-  * decreases viability of malignant cell lines(({{pubmed>long:28666209}}))
+  * decreases viability of malignant cell lines(({{pmid>long:28666209}}))
-  * carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques  (({{pubmed>long:19124398}}))
+  * carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques  (({{pmid>long:19124398}}))
-  * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}}))
+  * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pmid>long:25891757}}))
-  * improvement of glycemic control & insulin resistance was only observed in olmesartan group  (({{pubmed>long:23303198}}))
+  * improvement of glycemic control & insulin resistance was only observed in olmesartan group  (({{pmid>long:23303198}}))
-  * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes  (({{pubmed>long:25275251}}))
+  * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes  (({{pmid>long:25275251}}))
-  * prevention of microalbuminuria in patients with type 2 diabetes and hypertension  (({{pubmed>long:22418908}}))
+  * prevention of microalbuminuria in patients with type 2 diabetes and hypertension  (({{pmid>long:22418908}}))
@@ Line 133: / Line 132: @@
  Patients receiving the highest dose of olmesartan (40 and 80 mg) had an inward carotid remodeling and were shifted toward a lower elastic modulus at a given circumferential wall stress, indicating an improvement in the intrinsic elastic properties of the carotid artery wall material. These data suggest that 40 and 80 mg olmesartan were able to significantly remodel and destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg.
-//hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint  (({{pubmed>long:25001274}}))
+//hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint  (({{pmid>long:25001274}}))
 {{tag>olmesartan Food_and_drink summary}}

home/food/aim_health/aging.1586559957.txt.gz · Last modified: 04.10.2020 by sallieq